New Zinx Cough Kit™ and Zinx Cold Kit™ Give Sufferers a Convenient Solution to Effectively Treat Symptoms Associated with the Common Cold

LOS ANGELES - Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia, today launched its Zinx™ line of cold remedy products.

The new Zinx family of products includes prescription and over-the-counter products that use a unique patent-protected zinc formulation clinically proven to reduce the duration and severity of the common cold. Zinx Lozenges are available without a prescription, and two convenience kits, Zinx Cold Kit™ and Zinx Cough Kit™, are the first prescription products to include zinc lozenges.

Auriga will market Zinx to physicians and pharmacists through its expanding 200 member national sales force and beginning with the launch of www.zinxlozenges.com, Auriga will also go direct-to-consumer through a nation-wide print and internet promotional campaign. Zinx Lozenges will be distributed nationally through traditional pharmacies as well as through a popular on-line pharmacy retailer.

Zinx Lozenges are a novel zinc formulation employing the principles demonstrated in two independent, randomized, double-blind, placebo-controlled clinical trials published in peer-reviewed medical journals to dramatically reduce the duration and severity of common cold symptoms. Numerous zinc products are available; however, the patented formulation of Zinx has the highest level of zinc ion availability (ZIA). The efficacy of a zinc lozenge is tied to its ZIA. It is the lozenge ZIA value, in addition to the appropriate amount of zinc contained within the lozenge, which affects the duration of a cold. This unique formulation is protected by multiple <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />U.S. patents.

The Zinx Cough Kit and Zinx Cold Kit contain Zinx Lozenges to reduce the severity and duration of the common cold as well as prescription drug products for symptomatic relief of various cold symptoms. The Zinx Kits provide a unique option for treating the common cold: a 2-pronged approach packaged together for the convenience of both patients and physicians.

"We are excited to offer healthcare professionals and their patients this unique and highly effective product and be able to tell the compelling clinical story behind Zinx Lozenges," said Philip S. Pesin, CEO of Auriga. "The addition of Zinx to our respiratory franchises, Extendryl® and Levall®, expands the options for doctors looking for treatment alternatives for their patients suffering from one of the most common human physical ailments. Zinx gives a boost to our sales representatives who now have yet another strong product in their arsenal."

Reference

Prasad et al., "Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate." Annals of Internal Medicine. 2000. pp. 245-252.

Petrus, E. J., Lawson, K. A., Bucci, L. R. and Blum, K. (1998) Randomized, double-masked, placebo-controlled, clinical study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects. Curr. Ther. Res. 59:595-607.

About Auriga Laboratories™

Auriga Laboratories is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing, and advanced in-house drug development capabilities. The company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive prescription product portfolio currently includes Aquoral™ for the treatment of xerostomia, Akurza™ and Xyralid™ dermatology products, and the Zinx™, Extendryl®, and Levall® families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the company's ability to secure additional financing, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's ability to find and execute strategic transactions, its potential exposure to litigation, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.

Contact:
Company contact:
Auriga Laboratories, Inc.
Andrew D. Shales, Chief Operating Officer, 678-282-1613
Fax: 678-282-1683
ashales@aurigalabs.com

or

Investor Relations:
Liolios Group, Inc.
Ron Both, 949-574-3860
ron@liolios.com